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Abstract
Background: We investigated the distribution and clinical significance of mobilized endothelial progenitor cells
(EPCs) in hepatocellular carcinoma (HCC). We found that many more EPCs were recruited to nonmalignant liver
tissue (especially into adjacent non-tumor tissues (AT)) than to tumor vessels. These results suggest that the
mechanism underlying the recruitment of EPCs into microvessels in AT merits further investigation
Methods: Angiogenic factors were detected in three tissue microarrays comprising normal liver, paired tumor
tissue (TT) and AT from 105 patients (who had undergone hepatectomy for HCC) using immunohistochemistry.
Also, the number of EPCs (positive for Sca-1, Flk-1 and c-Kit) in the blood and liver of cirrhotic mice were
determined by flow cytometry and immunohistochemistry. The distribution of these labeled EPCs in tumor and
non-tumor tissues was then studied.
Results: The results from the tissue microarrays showed that the expression levels of VEGF-A, bFGF, TGF-b, MCP-1,
TSP-1, MMP-9, TIMP-2, and endostatin were significantly higher in AT than in either normal liver or TT (p < 0.05),
but no significant difference was found in the expression levels of COX-2 and NOS-2 between AT and TT. The
expression of VEGF-A, bFGF, TGF-b, MCP-1, TSP-1, MMP-9, TIMP-2, endostatin, COX-2, and NOS-2 in normal liver
tissue was weaker than that in AT or TT. In cirrhotic mice, the number of circulating endothelial progenitor cells
gradually increased, before decreasing again. In this mouse model, increased numbers of EPCs were recruited and
homed specifically to the cirrhotic liver.
Conclusions: Both liver cirrhosis and HCC led to increased expression of pro-angiogenic factors, which resulted in
the recruitment of EPCs into AT. Also, EPCs were mobilized, recruited and homed to cirrhotic liver. The unique
pathology of HCC coupled with liver cirrhosis may, therefore, be associated with the distribution and function of
EPCs.
Background
It is generally accepted that tumors are endowed with
angiogenic capabilities, and that their growth, invasion
and metastasis are angiogenesis-dependent. Over the
past several years, a substantial amount of evidence
from both animal and human studies suggests that
neoangiogenesis involves endothelial progenitor cells
(EPCs) as well as endothelial cells (ECs) co-opted from
the surrounding vessels [1-3]. Some studies have
reported that EPCs are mobilized, recruited and home
with high specificity to solid tumors [4,5]. Therefore,
EPCs might be useful for the early detection of tumors,
for distinguishing benign from malignant disease, for
determining prognoses, predicting the response to ther-
apy, and monitoring the clinical course [6-8]. However,
our previous studies of hepatocellular carcinoma (HCC)
suggest that many more EPCs are recruited into non-
malignant liver tissue, especially into adjacent
non-tumor tissues (AT), than are recruited into tumor
vessels [9]. The mechanism underlying this increased
recruitment into microvessels in AT is unknown.
The recruitment and homing of EPCs is affected by
hypoxia, angiogenic factors, and adhesion molecules
* Correspondence: drdingyitao@sina.com
† Contributed equally
1Institute of Hepatobiliary Surgery, Affiliated Drum Tower Hospital, School of
Medicine, Nanjing University, Nanjing, Jiangsu Province, China
Full list of author information is available at the end of the article
Yu et al. BMC Cancer 2010, 10:435
http://www.biomedcentral.com/1471-2407/10/435
© 2010 Yu et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.[10]. These factors are also relevant to HCC with liver
cirrhosis [11-13]. HCC is associated, in most cases, with
chronic liver diseases including chronic viral hepatitis
and cirrhosis, especially in Southeast Asia. The pathol-
ogy of HCC with liver cirrhosis may be an important
factor in the distribution, contribution, and differentia-
tion of EPCs.
Therefore, in this study, the distribution and expres-
sion levels of angiogenic factors related to the mobiliza-
tion and recruitment of EPCs were evaluated using
HCC tissue microarrays. Also, using a mouse model of
liver cirrhosis, the number of endothelial progenitor
cells in the circulation and tissues was also determined
to evaluate their mobilization, recruitment, and distribu-
tion characteristics.
Methods
Tissue arrays
Patients and tissue samples: a group of 105 patients with
HCC received curative resection in the Department of
Hepatobiliary Surgery in Nanjing Drum Tower Hospital,
Medical College of Nanjing University. The mean age of
these patients was 50.0 years (50.0 ± 12.5 years). In 72
of these patients (68.6%), the disease was associated with
liver cirrhosis, and 85 patients (81.0%) were positive for
serum hepatitis B surface antigen. The mean size of the
resected HCC in this study was 7.3 cm. Sixty-six
patients had a large tumor (maximum diameter > 5 cm),
39 had a small tumor (maximum diameter ≤5c m ) ,a n d
48 had multiple tumors (more than two nodules). Before
surgery, no chemotherapy or other treatment was given
and none of the patients had extra-hepatic metastasis.
In addition, 44 liver tissue samples without evidence of
HCC or liver cirrhosis were used as negative controls.
A tissue microarray was constructed as previously
described [14]. Briefly, surgical specimens were fixed in
10% formalin and embedded in paraffin. In accordance
with the Classification of Carcinomas of the Liver (Modi-
fied) proposed by UICC, sections (4 μm thick) were cut
from the blocks and stained with hematoxylin and eosin
(H&E) to study the pathological features of HCC [15].
Representative regions of the blocks were identified on
the H&E-stained sections and cylindrical tissue cores (1
mm in diameter) were prepared using a tissue microarray
constructor (Beecher Instruments MTA-1, Silver Spring,
MD, USA). Two cores (paired tumor tissue (TT) and
AT) from each donor block were inserted into a pre-
formed recipient block to produce a tissue array block.
Thereafter, 4 μm thick consecutive sections were cut
from the array block for immunohistochemical staining.
Immunohistochemical staining
Using the tissue array, the expression and distribution of
17 angiogenic biomarkers were evaluated
immunohistochemically. These included the165-amino
acid isoform of vascular endothelial growth factor
(VEGF-A), basic fibroblast growth factor (bFGF; Santa
Cruz), matrix metalloproteinase-9 (MMP-9), endostatin,
tissue inhibitor of metalloproteinases-1 and -2 (TIMP-1,
TIMP-2), thrombospondin-1 (TSP-1; (Neomarker), p53,
transforming growth factor-b (TGF-b), cyclooxygenase 2
(COX-2; DAKO), and monocyte chemotactic protein 1
(MCP-1; Chemicon). Briefly, tissue sections were de-
waxed in xylene, dehydrated in ethanol, and then treated
with 3% hydrogen peroxidase for 30 min to block endo-
genous peroxidase activity. After incubation with 10%
normal goat serum for 20 min to reduce non-specific
binding, the sections were incubated with primary anti-
bodies over night at 4°C. The sections were then incu-
bated with the corresponding secondary antibody for
30 min followed by visualization using 3, 3’-diaminoben-
zidine. An immunoglobulin-negative control was used
to rule out nonspecific binding.
Immunohistochemical staining was assessed by two
independent investigators without any knowledge of the
corresponding clinicopathological data. Positive cells
were counted in representative areas of the sections and
expressed as a percentage. The level of immunostaining
was categorized into three grades: - = negative; 5%-50% =
low; >50% = moderate-high, as reported by Au NH [16]
EPCs labeled with CM-Dil
Mouse bone marrow derived EPCs were induced and
cultured using the EGM-2 MV Bullet Kit (CC-3202,
Clonetics/BioWhittaker) as in our previous study [9].
After passaging three times, EPCs were digested with
0.05% trypsin and resuspended in PBS. EPCs were
labeled with CM-Dil (Molecular Probes Inc., USA)
according to the method of Ferrari [17]. CM-Dil was
dissolved in DMSO (final concentration of 1 mg/ml).
EPCs (10
6 cells) were incubated in 2 μL CM-Dil at 37°C
for 5 min, followed by 4°C for 15 min, washed twice
with PBS and suspended in EGM-2 medium. The per-
centage EPCs positive for CM-Dil was evaluated by flow
cytometry.
Animal model of liver cirrhosis
This study used 8-week-old Kunming male mice weigh-
ing 20 grams. Liver cirrhosis was induced by subcuta-
neous injection of 10% CCI4 (100 μL) every third week
for three months and drinking water containing 8%
alcohol. Animal care and experimental procedures were
approved by the research ethics committee of Drum
Tower Hospital.
EPC transplantation
Labeled EPCs (10
6 cells) were infused into cirrhotic
mice via the tail vein. After 48 hours, the liver, lungs,
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Page 2 of 10Figure 1 Immunohistochemical staining of VEGF-A, bFGF, TGF-b,M C P - 1 ,T S P - 1i nt i s s u e s . Representative sections showing
immunohistochemical staining of VEGF-A (A, B, and C), bFGF (D, E, and F), TGF-b (G, H, and I), MCP-1 (J, K, and L), TSP-1 (M, N, and O) in healthy
controls (A, D, G, J, and M), adjacent non-tumor tissues (B, E, H, K, and N) and tumor tissues (C, F, I, L, and O). The signals were detected by DAB
staining.
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Page 3 of 10Figure 2 Immunohistochemical staining of MMP-9, TIMP-1, TIMP-2, endostatin, COX-2, and NOS-2 in tissues.R e p r e s e n t a t i v es e c t i o n s
showing immunohistochemical staining of MMP-9 (A, B, and C), TIMP-1 (D, E, and F), TIMP-2 (G, H, and I), endostatin (J, K, and L), COX-2 (M, N,
and O), and NOS-2 (P, Q, and R) in healthy controls (A, D, G, J, M, and P), adjacent non-tumor tissues (B, E, H, K, N, and Q) and tumor tissues
(C, F, I, L, O, and R). The signals were detected by DAB staining.
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Page 4 of 10spleen, and kidneys were excised, embedded in OCT
and stored in liquid nitrogen. Tissue slices (4 μm thick)
were observed using a fluorescence microscope.
Flow cytometry
EPCs in the circulating unselected peripheral blood cell
population from cirrhotic mice were measured by flow
cytometry at 0, 2, 4, 8 and 12 weeks. EDTA-anti-coagu-
lated blood (100 μL) was incubated for 30 min at 4°C
with 5 μL phycoerythrin-conjugated anti-Flk-1 (Miltenyi
Biotec, Germany), PerCP-conjugated anti-c-Kit, or
FITC-conjugated anti-Sca-1 (Beckton Dickinson, Heidel-
berg, Germany). IgG1-FITC and IgG2a-phycoerythrin
antibodies (B&D) served as isotype controls for each
procedure. After incubation, cells were lysed and washed
with PBS before analysis. A minimum of 50,000 events
were acquired for each sample. Quantitative fluores-
cence analysis was done using FACSCalibur and
WinMDI software (B&D).
Results
Higher expression of angiogenic factors in adjacent non-
tumor tissues than in tumor tissues
The mobilization, recruitment and homing of EPCs to
tumor tissues are multi-step events requiring the partici-
pation of multiple factors, including angiogenic factors,
adhesion molecules, tumor cells, ECs, and stromal cells
[10,18]. Our previous studies showed higher expression
of VEGF, HIF-1a, CD105 and AC133 in AT [9,19].
Therefore, we hypothesized that AT might be hypoxic
a n da na r e ao fa c t i v ea n g i o g e n e s i s .T oc o n f i r mt h i s ,w e
evaluated the expression of some key angiogenic factors,
including activator molecules (VEGF-A, bFGF, TGF-b,
MCP-1, MMP-9, TSP-1), inhibitor molecules (endosta-
tin, TIMP-1, TIMP-2), and the transcript factors (COX-
2, NOS-2), in AT and TT using HCC tissue arrays.
Immunoreactivity to VEGF-A, bFGF, TGF-b,M C P - 1 ,
TSP-1, TIMP-1, TIMP-2, and endostatin was observed
mainly in HCC cells and hepatocytes, showing a predo-
minant cytoplasmic staining with positive liver cells dis-
tributed throughout the tumor tissue and the
surrounding liver (Figures 1 and 2). Cytoplasmic and
nuclear staining for COX-2 and NOS-2 was observed in
both tumor cells and non-tumor connective tissue cells,
including sinusoidal endothelial cells.
The expression of VEGF-A, bFGF, TGF-b,M C P - 1 ,
MMP-9, TSP-1, TIMP-2, and endostatin was signifi-
cantly higher in AT than in normal liver or TT (p <
0.01 and 0.05, respectively), while no significant differ-
ence was found in the levels of TIMP-1, COX-2, and
NOS-2 between TT and AT. Meanwhile, constitutive
expression of VEGF-A, bFGF, TGF-b,M C P - 1 ,T S P - 1 ,
MMP-9, TIMP-2, and endostatin in normal liver tissue
was weaker than that in AT or TT tissues (Table 1, Fig-
ures 1 and 2). This suggests that AT is hypoxic and is
an area of active angiogenesis, resulting in increased
recruitment of EPCs.
Bone marrow EPCs are mobilized and recruited into
cirrhotic liver
In general, EPCs are recruited into tumor tissues [4-8].
However, in HCC many more EPCs are recruited into
AT than into TT [9]. In Southeast Asia, 80% of patients
with HCC also have hepatitis or liver cirrhosis. There-
fore, the particular pathology of HCC with concomitant
liver cirrhosis may play an important role in the distri-
bution of EPCs.
Sca-1, Flk-1, and c-Kit are surface markers of mouse
EPCs [20,21]. EPCs in the circulation and livers of cir-
rhotic mice were analyzed by flow cytometry and immu-
nohistochemical staining. The number of circulating
EPCs gradually increased up to 4 weeks after disease
Table 1 Expression and distribution of angiogenic molecules in HCC tissue arrays
HC AT HCC
(-) (+) (++) Positive Percent (-) (+) (++) Positive Percent (-) (+) (++) Positive Percent
VEGF-A 35 3 6 20.5% 43 9 46 56.1%** 41 29 27 57.7%^^
##
bFGF 27 4 13 38.6% 29 13 55 70.1%** 32 41 23 66.7%^^
##
TGF-b 20 8 16 54.5% 11 4 83 88.8%** 14 15 68 85.6%^^
#
MCP-1 20 8 8 44.4% 32 21 44 67.0%* 59 21 17 39.2%
##
TSP-1 38 4 1 11.6% 43 14 41 56.1%** 37 33 27 61.9%^^
##
MMP-9 28 7 9 36.4% 25 13 59 74.2%** 40 23 35 59.2%^
##
TIMP-1 24 2 13 38.5% 63 14 17 33.0% 69 10 17 28.1%
TIMP-2 21 6 17 52.3% 19 13 66 80.6%** 26 37 35 73.5%^^
##
Endostatin 23 9 10 45.2% 14 9 75 85.7%** 37 21 40 62.2%
##
COX-2 25 9 10 43.2% 7 39 51 92.8%** 9 46 43 90.8%^^
NOS-2 32 9 3 27.3% 37 21 40 62.2%** 43 30 25 56.1%^^
*p < 0.05, **p < 0.01, AT versus HC;
#p < 0.05,
##p < 0.01, HCC versus AT, ^p < 0.05; ^^p < 0.01, HCC versus HC
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Page 5 of 10Figure 3 Dynamic changes in the levels of circulating EPCs during liver cirrhosis. The mean percentage of Sca-1, c-Kit and Flk-1 positive
cells is shown (n = 5) during liver cirrhosis (0, 2, 4, 8 and 12 weeks post disease onset).
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Page 6 of 10onset and then deceased gradually (Figure 3 and Addi-
tional file 1). Moreover, consistent with the distribution
of AC133-positive cells found in our previous study of
human HCC with cirrhosis, increasing numbers of Sca-1
positive cells were observed in the cirrhotic livers, espe-
cially in the portal areas (Figure 4) [9].
EPCs are recruited and home with high specificity to
cirrhotic liver
EPCs labeled with CM-Dil were used to evaluate the
bio-distribution of EPCs in mice with liver cirrhosis.
Flow cytometry showed that the majority (94.5%) of
EPCs were labeled with CM-Dil (Additional file 2).
Approximately 10
6 CM-Dil-labeled EPCs were infused
into the tail vein and the liver, lungs, spleen, and kid-
neys were excised 48 hours later and embedded in
OCT. Fluorescence microscopy showed high numbers of
labeled EPCs in the portal areas of the cirrhotic livers,
but few EPCs in the lungs, spleen, or kidneys (Figure 5).
This clearly indicates that EPCs were recruited and
homed with high specificity to the cirrhotic liver.
Discussion
Neoangiogenesis involves EPCs as well as ECs co-opted
from surrounding blood vessels. The mobilization,
recruitment, homing and incorporation of EPCs into
tumors are independent multi-step events in tumor
vasculogenesis. This complex process requires the parti-
cipation of multiple growth factors, tumor cells, ECs,
stromal cells and EPCs in the tumor microenvironment
[18,22,23]. Pro-angiogenic factors such as the VEGF-A,
bFGF, and MCP-1 are involved in the activation, mobili-
zation and recruitment of EPCs from the bone marrow
and in promoting the differentiation of EPCs into ECs
in some ischemic diseases and during tumor growth
[24,25]. Studies have found that there is higher expres-
sion of many angiogenic factors and increased recruit-
ment of EPCs into non-tumor tissues compared with
tumors. This is supported by this current study and our
previous study [9,19]. Furthermore, these factors activate
MMPs, particularly MMP-9, leading to the release of
soluble Kit ligand which, in turn, promotes cell prolif-
eration and motility within the bone marrow [17,26].
Also, the expression of adhesion molecules that enable
the homing of EPCs is higher in AT (Additional file 3
and 4).
Because ECs in the liver release a battery of different
CC chemokines, it is possible that these CC chemokines
p l a yar o l ei nE P Ch o m i n gt oH C Cl i v e rt i s s u e s .I ti s
worth noting that there are more active ECs in AT [19].
It is not the tumor tissue itself, but the EC component
of the tumor-induced stroma, that is responsible for
recruiting EPCs. Our data also suggest that EPCs are
recruited and home with high specificity to tumor
Figure 4 Distribution of Sca-1 positive cells in cirrhotic liver during cirrhosis. Representative sections showing distribution of Sca-1 positive
cells in cirrhotic liver at 0 week (control, A), and at 2 weeks (B), 4 weeks (C), and 8 weeks (D). The signals were detected by DAB staining.
Magnification: ×200.
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Page 7 of 10tissues in an HCC mouse model without liver cirrhosis
(unpublished data). Therefore, HCC coupled with cir-
rhosis provides a microenvironment that encourages the
homing of EPCs.
In this study, the expression of angiogenic factors such
as VEGF-A, bFGF, TGF-b,M C P - 1 ,T S P - 1 ,M M P - 9 ,
TIMP-2, and endostatin in AT was significantly higher
than that in normal liver and HCC tissues. Many studies
also report higher expression of proangiogenic factors
such as VEGF-A [27-29], hepatic growth factor (HGF)
[30], HIF-1a [19], and inducible nitric oxide [31] in the
surrounding liver than in the tumor tissues. Moreover,
increased levels of macrophage colony-stimulating factor
and increased numbers of macrophages were found in
peri-tumoral liver tissues than in the tumor tissue itself
[32,33]. Of note, inhibitors of angiogenesis were also
up-regulated along with the activators. Consistent with
this, our previous study showed that the blood vessel
density was higher in peri-tumoral tissues than in
tumors [19]. Therefore, angiogenesis occurring in HCC
with liver cirrhosis was different from that in other
tumors. Most angiogenic factors showed higher expres-
sion levels in non-tumor tissues, which might be a
reflection of both cirrhosis and a “field effect” relevant
to the tumor. Taken together these studies suggest that
the peri-tumoral tissues in HCC are an area of active
angiogenesis.
However, the mechanism by which angiogenic factors
are over-expressed in the peri-tumoral liver tissue
remains unclear. HCC is a cancer associated, in most
cases, with chronic liver diseases such as chronic viral
hepatitis and cirrhosis, especially in Southeast Asia. The
Figure 5 Biodistribution of CM-Dil-labeled-EPCs in the cirrhotic mouse. Representative sections showing biodistribution of CM-Dil-labeled-
EPCs (A, B) in liver (C), lung (D), kidney (E) and spleen (F). Magnification: ×40.
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Page 8 of 10nonmalignant liver itself undergoes a precancerous
change resulting in increased angiogenesis. During liver
cirrhosis, fibrogenesis results in intrahepatic shunts and
a barrier between the sinusoids and hepatocytes [34]
generating areas of hypoxia. Our study indicates that the
expression of HIF-1a, COX-2 and NOS-2 (which regu-
late the expression of many pro- and anti-angiogenic
factors) is elevated in AT compared with TF and TT.
This suggests that the distribution and expression of
these angiogenic factors results from liver cirrhosis.
In the present study, we found that the high expres-
sion of angiogenic factors in the peri-tumoral liver tis-
sue, but not in tumor tissue, was consistent with
increasing microvessel density and EPC numbers. In
addition, it is known that the MMPs and TIMPs upre-
gulated in AT may be involved in the progression of
HCC [35]. Therefore, the peri-tumoral tissues in HCC
are an area of active angiogenesis, which may provide a
microenvironment conducive for intrahepatic metastasis
and tumor recurrence after resection. This is an impor-
tant, but often neglected, issue. Together with these
results, the present study implies that post-operative
adjuvant therapies should target not only the residual
tumor cells, but also the residual cirrhotic liver, which
provides the microenvironment for intrahepatic metasta-
sis and tumor recurrence. We propose that the
peri-tumoral microenvironment is very important to
understanding the mechanism of intrahepatic metastasis
of HCC and in shaping the post-operative strategy for
prevention of recurrence after hepatectomy.
Conclusions
The present study shows that angiogenic factors
expressed by peri-tumoral cells are responsible for the
recruitment of EPCs and that the particular pathology
found in HCC with liver cirrhosis may play an impor-
tant role in the distribution, origin, and differentiation
of EPCs. The results also highlight the fact that the
peri-tumoral microenvironment may play an important
role in tumor recurrence and metastasis after hepatect-
omy. Therefore, EPCs may be potential new targets or
vectors for adjuvant therapy.
Additional material
Additional file 1: Dynamics changes of circulating EPCs during liver
cirrhosis. The percent of c-Kit and Flk-1, Sca-1 and c-Kit, Sca-1 and Flk-1
positive cells was compared at 2, 4, 8 and 12 weeks versus 0 weeks (n =
5). *p < 0.05, **p < 0.01, c-Kit and Flk-1 positive cells;
#p < 0.05,
##p <
0.01, Sca-1 and c-Kit positive cells; $ p < 0.05; $$ p < 0.01, Sca-1 and Flk-
1 positive cells.
Additional file 2: EPCs labeled with CM-Dil were validated.
Representative sections showed that EPCs were validated with FACS
before (A, 2%) and after (B, 96.5%) being labeled with CM-Dil.
Additional file 3: Immunohistochemical staining of fibronectin in
adjacent non-tumor tissues and tumor tissues. Representative
sections showing immunohistochemical staining of fibronectin in
adjacent non-tumor tissues (A) and tumor tissues (B) (n = 30). The signals
were detected by DAB staining. Magnification: ×200.
Additional file 4: Immunohistochemical staining of VCAM-1 in
normal liver, adjacent non-tumor tissues and tumor tissues.
Representative sections showing immunohistochemical staining of
VCAM-1 in normal liver (A), adjacent non-tumor tissues (B) and tumor
tissues (C) (n = 30). The signals were detected by DAB staining.
Magnification: ×200.
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